These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 22421959)

  • 21. A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia.
    Gray B; Bagnall RD; Lam L; Ingles J; Turner C; Haan E; Davis A; Yang PC; Clancy CE; Sy RW; Semsarian C
    Heart Rhythm; 2016 Aug; 13(8):1652-60. PubMed ID: 27157848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-natal heart adaptation in a knock-in mouse model of calsequestrin 2-linked recessive catecholaminergic polymorphic ventricular tachycardia.
    Valle G; Boncompagni S; Sacchetto R; Protasi F; Volpe P
    Exp Cell Res; 2014 Feb; 321(2):178-89. PubMed ID: 24370574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of SR Ca release by luminal Ca and calsequestrin in cardiac myocytes: effects of CASQ2 mutations linked to sudden cardiac death.
    Terentyev D; Kubalova Z; Valle G; Nori A; Vedamoorthyrao S; Terentyeva R; Viatchenko-Karpinski S; Bers DM; Williams SC; Volpe P; Gyorke S
    Biophys J; 2008 Aug; 95(4):2037-48. PubMed ID: 18469084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation.
    Novak A; Barad L; Zeevi-Levin N; Shick R; Shtrichman R; Lorber A; Itskovitz-Eldor J; Binah O
    J Cell Mol Med; 2012 Mar; 16(3):468-82. PubMed ID: 22050625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of mutant protein level in autosomal recessive catecholamine dependent polymorphic ventricular tachycardia (CPVT2).
    Katz G; Shainberg A; Hochhauser E; Kurtzwald-Josefson E; Issac A; El-Ani D; Aravot D; Afek A; Seidman JG; Seidman CE; Eldar M; Arad M
    Biochem Pharmacol; 2013 Dec; 86(11):1576-83. PubMed ID: 24070655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Probing cationic selectivity of cardiac calsequestrin and its CPVT mutants.
    Bal NC; Jena N; Sopariwala D; Balaraju T; Shaikh S; Bal C; Sharon A; Gyorke S; Periasamy M
    Biochem J; 2011 Apr; 435(2):391-9. PubMed ID: 21265816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impaired Dynamic Sarcoplasmic Reticulum Ca Buffering in Autosomal Dominant CPVT2.
    Wleklinski MJ; Kryshtal DO; Kim K; Parikh SS; Blackwell DJ; Marty I; Iyer VR; Knollmann BC
    Circ Res; 2022 Sep; 131(8):673-686. PubMed ID: 36102198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conditional ablation and conditional rescue models for Casq2 elucidate the role of development and of cell-type specific expression of Casq2 in the CPVT2 phenotype.
    Flores DJ; Duong T; Brandenberger LO; Mitra A; Shirali A; Johnson JC; Springer D; Noguchi A; Yu ZX; Ebert SN; Ludwig A; Knollmann BC; Levin MD; Pfeifer K
    Hum Mol Genet; 2018 May; 27(9):1533-1544. PubMed ID: 29452352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations.
    Novak A; Barad L; Lorber A; Gherghiceanu M; Reiter I; Eisen B; Eldor L; Itskovitz-Eldor J; Eldar M; Arad M; Binah O
    J Cell Mol Med; 2015 Aug; 19(8):2006-18. PubMed ID: 26153920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of sarcoplasmic reticulum calcium release by calsequestrin in cardiac myocytes.
    Györke S; Györke I; Terentyev D; Viatchenko-Karpinski S; Williams SC
    Biol Res; 2004; 37(4):603-7. PubMed ID: 15709687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ablation of HRC alleviates cardiac arrhythmia and improves abnormal Ca handling in CASQ2 knockout mice prone to CPVT.
    Liu B; Ho HT; Brunello L; Unudurthi SD; Lou Q; Belevych AE; Qian L; Kim DH; Cho C; Janssen PM; Hund TJ; Knollmann BC; Kranias EG; Györke S
    Cardiovasc Res; 2015 Nov; 108(2):299-311. PubMed ID: 26410369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single delivery of an adeno-associated viral construct to transfer the CASQ2 gene to knock-in mice affected by catecholaminergic polymorphic ventricular tachycardia is able to cure the disease from birth to advanced age.
    Denegri M; Bongianino R; Lodola F; Boncompagni S; De Giusti VC; Avelino-Cruz JE; Liu N; Persampieri S; Curcio A; Esposito F; Pietrangelo L; Marty I; Villani L; Moyaho A; Baiardi P; Auricchio A; Protasi F; Napolitano C; Priori SG
    Circulation; 2014 Jun; 129(25):2673-81. PubMed ID: 24888331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia.
    Shan J; Xie W; Betzenhauser M; Reiken S; Chen BX; Wronska A; Marks AR
    Circ Res; 2012 Aug; 111(6):708-17. PubMed ID: 22828895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
    Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
    Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Compound heterozygous CASQ2 mutations and long-term course of catecholaminergic polymorphic ventricular tachycardia.
    Josephs K; Patel K; Janson CM; Montagna C; McDonald TV
    Mol Genet Genomic Med; 2017 Nov; 5(6):788-794. PubMed ID: 29178653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular adaptation to calsequestrin 2 (CASQ2) point mutations leading to catecholaminergic polymorphic ventricular tachycardia (CPVT): comparative analysis of R33Q and D307H mutants.
    Valle G; Arad M; Volpe P
    J Muscle Res Cell Motil; 2020 Sep; 41(2-3):251-258. PubMed ID: 32902830
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis.
    Priori SG; Chen SR
    Circ Res; 2011 Apr; 108(7):871-83. PubMed ID: 21454795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Viral delivered gene therapy to treat catecholaminergic polymorphic ventricular tachycardia (CPVT2) in mouse models.
    Kurtzwald-Josefson E; Yadin D; Harun-Khun S; Waldman M; Aravot D; Shainberg A; Eldar M; Hochhauser E; Arad M
    Heart Rhythm; 2017 Jul; 14(7):1053-1060. PubMed ID: 28336343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Catecholaminergic polymorphic ventricular tachycardia-related mutations R33Q and L167H alter calcium sensitivity of human cardiac calsequestrin.
    Valle G; Galla D; Nori A; Priori SG; Gyorke S; de Filippis V; Volpe P
    Biochem J; 2008 Jul; 413(2):291-303. PubMed ID: 18399795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of the first induced pluripotent stem cell line generated from a patient with autosomal dominant catecholaminergic polymorphic ventricular tachycardia due to a heterozygous mutation in cardiac calsequestrin-2.
    Ross S; Holliday M; Lim S; Semsarian C
    Stem Cell Res; 2019 May; 37():101450. PubMed ID: 31039485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.